CClinicalTrials.gg
CompletedNCT01744249Updated Apr 28, 2026Results posted

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

A Phase 2/3 interventional study of Axitinib and Sandostatin LAR in Neuroendocrine Tumors and Advanced Cancer, sponsored by Grupo Espanol de Tumores Neuroendocrinos. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Grupo Espanol de Tumores Neuroendocrinos · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Assess whether therapy with axitinib, a potent angiogenic inhibitor of the tyrosine kinase receptors of VEGF bioavailable by oral administration, is capable of improving PFS in patients with advanced G1-G2 NETs of nonpancreatic origin with progressive disease documented in the 12 months prior to entering the study.

Read the detailed description

Phase II/III, prospective, multicenter, randomized (1:1), double-blind study to evaluate the efficacy and tolerability of axitinib in patients diagnosed with advanced G1-G2 neuroendocrine tumors (WHO 2010) of nonpancreatic origin that have presented documented disease progression in the 12 months prior to entering the study. In the first part of the study (Phase II), 105 patients were enrolled. The second part of the study is the expansion to Phase III, which is expected to include 148 additional patients. Patients will be randomized to receive Sandostatin LAR with axitinib or Sandostatin LAR with placebo until disease progression or unacceptable toxicity occurs. Randomization will be stratified by the time from diagnosis to enrollment in the study (more vs less than or equal to 12 months), the origin of the primary tumor (gastrointestinal tract vs non-gastrointestinal tract [lung or other sites]) and ki-67 (\< 5% vs > 5%).

02

Conditions studied

  • Neuroendocrine Tumors
  • Advanced Cancer

Browse trials for

Keywords

  • Advanced neuroendocrine tumours of non-pancreatic origin
  • axitinib
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. G1-G2 neuroendocrine tumor (WHO 2010) of histologically confirmed non-pancreatic origin, functioning and nonfunctioning
  2. Metastatic or locally advanced disease not amenable to treatment with curative intent
  3. Clinical and/or radiological disease progression documented in the 12 months prior to study entry.
  4. Patients should have at least one measurable lesion as defined by RECIST 1.1 criteria. Patients should not have undergone local or regional ablative procedures (embolization, cryoablation, radiofrequency ablation, or others) in the 6 months prior to entering the study, unless there are other locations of measurable disease or clear radiological progression after carrying out these procedures (in these cases, local and regional ablation procedures shall be permitted if they have been performed at least 1 month prior to enrollment in the study).
  5. Ki-67 \< 20%
  6. Prior treatment with somatostatin analogues is allowed
  7. Prior treatment with interferon is allowed
  8. Prior treatment is allowed with up to 2 antineoplastic systemic treatment lines different from SAs or IFN (systemic treatment is understood as conventional cytotoxic chemotherapy or new drugs for therapeutic targets as mTOR or other, as long as it is not directed against VEGF/VEGFR). Treatment with SAs or IFN does not count as prior lines of antineoplastic treatment.
  9. Prior treatment with targeted therapy against VEGF or VEGFR is not allowed.
  10. Adequate organ function as defined by the following criteria:

    • Absolute neutrophil count ≥ 1500 cells/mm3,
    • Platelet count ≥ 75,000 cells/mm3,
    • Hemoglobin ≥ 9.0 g/dL,
    • AST y ALT ≤ 2.5 x upper limit of normal (ULN), except if liver metastases exist, in which case AST and ALT 5.0 ≤ x ULN is allowed,
    • Total bilirubin ≤ 1.5 x ULN,
    • Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min,
    • Proteinuria \< 2+ by reactive strip. If the reactive strip is ≥ 2+, a 24-hour urine sample should be collected and the patient may be eligible if urinary protein excretion is \< 2 g every 24 hours.
  11. Men or women aged ≥ 18 years.
  12. ECOG performance status 0-2
  13. Life expectancy ≥ 12 weeks
  14. At least 4 weeks should pass from the end of the previous systemic treatment with resolution of all treatment-related toxicities to grade ≤ 1 according to NCI CTCAE Version 4.0 or to baseline, except for alopecia or properly treated hypothyroidism.
  15. No prior evidence of uncontrolled hypertension should exist, as documented by 2 baseline blood pressure readings taken at least 1 hour apart. Baseline readings of systolic blood pressure should be ≤ 150 mm Hg and baseline readings of diastolic pressure should be ≤ 90 mm Hg. Patients whose hypertension is being controlled with antihypertensive therapy are eligible.
  16. Women (or their partners) should be surgically sterilized or postmenopausal, or must agree to use an effective contraceptive method during and for at least 6 months after receiving study treatment. All women of childbearing age should have a negative pregnancy test (serum/urine) within 7 days prior to starting treatment. Men (or their partners) should be surgically sterilized or must agree to use an effective contraceptive method during and for at least 6 months after receiving study treatment. The definition of an effective contraceptive method must comply with local regulations and will be based on the criterion of the principal investigator or a designated associate. Lactating women may not participate in this study.
  17. Signed and dated informed consent document stating that the patient has been informed of all the pertinent aspects of the trial prior to recruitment.
  18. Willingness and ability to comply with scheduled visits, treatment plans (including willingness to take axitinib or placebo according to randomization), laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

1. Subjects must be evaluated with regard to the following exclusion criteria:

  1. The following types of endocrine tumors will not be included: paraganglioma, adrenal endocrine tumor, thyroid, parathyroid, or pituitary.
  2. Major surgery within previous 4 weeks, or radiation therapy within 2 weeks prior to the start of treatment. Prior palliative radiotherapy for metastatic lesions is permitted if there is at least one measurable lesion that has not been irradiated (i.e., if there are other non-irradiated target lesions).
  3. Gastrointestinal abnormalities, including:

    • Inability to swallow oral medication;
    • Need for intravenous feeding;
    • Prior surgical procedures that affect absorption, including total gastric resection;
    • Treatment for active peptic ulcer in the last 6 months;
    • Uncontrolled active gastrointestinal bleeding unrelated to cancer, as evidenced by hematemesis, hematochezia or clinically significant melena in the last 3 months without evidence of resolution documented by endoscopy or colonoscopy;
    • Malabsorption syndromes;
  4. Current or anticipated need for treatment with drugs that are potent inhibitors of CYP3A4 (grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, and delavirdine) unless they can be replaced by another medication with minimal potential for CYP3A4/5 inhibition. The use of low-dose oral steroids (\< 5 mg/day prednisone or equivalent) is allowed. Co-administration of steroids may increase plasma concentrations of axitinib.
  5. Current use or anticipated need for treatment with drugs that are known potent CYP3A4/5 inducers (carbamazepine, dexamethasone, felbamate, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampicin, and St. John's wort) unless they can be replaced by another medication with minimal potential for CYP3A4 induction. Co-administration of CYP3A4/5 inducers may decrease plasma concentrations of axitinib.
  6. Need for anticoagulant therapy with oral vitamin K antagonists. Low doses of anticoagulants to maintain the patency of a central venous access device or to prevent deep vein thrombosis are permitted. Use with therapeutic doses of low molecular weight heparin is allowed.
  7. Clinically relevant history of bleeding in the last 6 months, including severe hemoptysis or hematuria, unless it has been due to a treated cause (e.g., completely resected bleeding intestinal tumor).
  8. Active epilepsy or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis.
  9. Serious uncontrolled illness or active infections that may interfere with the patient's ability to receive the study treatment.
  10. Any of the following events in the 12 months prior to administration of the study drug: myocardial infarction, uncontrolled angina, implantation of a coronary or peripheral bypass, symptomatic congestive heart failure, stroke or transient ischemic attack. Deep vein thrombosis or pulmonary embolism in the prior 6 months.
  11. Ongoing grade ≥ 2 cardiac arrhythmias according to NCI CTCAE: atrial fibrillation of any grade or QTc interval > 450 ms for men or > 470 ms for women.
  12. Patients with human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome-related disease.
  13. Prior history of cancer except those treated with curative intent for non-melanoma skin cancer in situ, breast or cervical cancer in situ, or those treated for any cancer with curative intent and no evidence of disease in the last 5 years prior to enrollment in the study.
  14. Dementia or significantly altered mental status that could prevent compression, or submission of informed consent and compliance with the requirements of this protocol.
  15. Any severe, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with participation in the study or with study drug administration, or that may interfere with the interpretation of results, and that could interfere with the patient's ability to take part in this study in the investigator's opinion.
  16. The patient's participation or intention to participate (in the 4 weeks prior to starting drug administration) in a study in which the patient will receive an investigational medicinal product.
  17. Subjects who are institutionalized by governmental or by judicial decision, or subjects who are dependent of the sponsor, the investigator or the trial site will be excluded from participation.
04

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Axitinib + Sandostatin LAR

    Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days

    Drug: Axitinib · Drug: Sandostatin LAR

  • Placebo comparator
    Placebo + Sandostatin LAR

    Placebo BID + Sandostatin LAR 30mg/28 days

    Drug: Sandostatin LAR · Drug: Placebo

Interventions

  • DrugAxitinib

    Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.

  • DrugSandostatin LAR

    Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity

  • DrugPlacebo

    orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.

05

What researchers measure

Primary outcomes

  1. Efficacy of Axitinib in Terms of PFS (Investigator Assessment)

    Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by investigators using tumor imaging computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months

Secondary outcomes

  1. Objective Response Rate (ORR) (Investigator Assessment)

    Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by investigators. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months

  2. Biochemical Response (5-OH-indoleacetic Acid and Chromogranin A)

    measurable in mL/ 24h and ng/ml respectively, through blood and urine test in patients with baseline elevation of CgA or 5-HIAA levels. This endpoint measures the negativization of these two tumor biomarkers.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months

  3. Safety and Tolerability of Axitinib (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE], Version 4.0)

    All adverse events and serious adverse events will be monitored with regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months

  4. Efficacy of Axitinib in Terms of PFS (Central Blinded Assessment)

    Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by central blinded reviewers using tumor imaging by computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months

  5. Objective Response Rate (ORR) (Central Blinded Assessment)

    Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by central blinded reviewers. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months

06

Results

Posted Apr 28, 2026

Participant flow

Patients enrolled and randomized

Participant flow — Overall Study
MilestoneAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
Started126130
Completed125130
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryEfficacy of Axitinib in Terms of PFS (Investigator Assessment)

Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by investigators using tumor imaging computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Reported as:
Median · months
Efficacy of Axitinib in Terms of PFS (Investigator Assessment)
monthsAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
Efficacy of Axitinib in Terms of PFS (Investigator Assessment)17.2 (13.6 to 24.7)13.1 (10.9 to 18.6)
Statistical analysis
  • Axitinib + Sandostatin LAR vs Placebo + Sandostatin LAR · Regression, Cox · p = 0.324 (Threshold of significance pre-established: P-value \< 0.05 will be statistically significant) · Cox proportional hazard: 0.86 · 95% CI 0.65 to 1.15
SecondaryObjective Response Rate (ORR) (Investigator Assessment)

Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by investigators. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) (Investigator Assessment)
ParticipantsAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
Complete response21
Partial response205
Stable disease8796
Progressive disease925
Not evaluable83
Statistical analysis
  • Axitinib + Sandostatin LAR vs Placebo + Sandostatin LAR · Chi-squared, Corrected · p = 0.007 (Threshold of significance pre-established: P-value \< 0.05 will be statistically significant)
SecondaryBiochemical Response (5-OH-indoleacetic Acid and Chromogranin A)

measurable in mL/ 24h and ng/ml respectively, through blood and urine test in patients with baseline elevation of CgA or 5-HIAA levels. This endpoint measures the negativization of these two tumor biomarkers.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Reported as:
Count of participants · Participants
Biochemical Response (5-OH-indoleacetic Acid and Chromogranin A)
ParticipantsAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
CgA response — Response3127
CgA response — No response3845
5-HIAA response — Response1916
5-HIAA response — No response2930
Statistical analysis
  • Axitinib + Sandostatin LAR vs Placebo + Sandostatin LAR · Fisher Exact · p = 0.407 (Threshold of significance pre-established: P-value \< 0.05 will be statistically significant)
  • Axitinib + Sandostatin LAR vs Placebo + Sandostatin LAR · Fisher Exact · p = 0.630 (Threshold of significance pre-established: P-value \< 0.05 will be statistically significant)
SecondarySafety and Tolerability of Axitinib (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE], Version 4.0)

All adverse events and serious adverse events will be monitored with regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assessed according to the National Institute of Health/National Cancer Institute (NIH/NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4)

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Reported as:
Count of participants · Participants
Safety and Tolerability of Axitinib (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE], Version 4.0)
ParticipantsAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
Any grade AEs — Yes, reported events121124
Any grade AEs — No, no events reported46
SAEs — Yes, reported events4830
SAEs — No, no events reported77100
Toxicities requiring end of treatment — Yes, reported events234
Toxicities requiring end of treatment — No, no events reported102126
Toxicities requiring treatment temporary interruption — Yes, reported events7655
Toxicities requiring treatment temporary interruption — No, no events reported4975
Toxicities requiring dose reductions — Yes, reported events4410
Toxicities requiring dose reductions — No, no events reported81120
SecondaryEfficacy of Axitinib in Terms of PFS (Central Blinded Assessment)

Calculated from the date of random assignment until the date of first progressive disease or death, whichever occurs first. Progression of the disease was assessed by central blinded reviewers using tumor imaging by computed tomography scans and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 PFS was analysed by Kaplan-Meier method and compared with log-rank tests. Patients alive with no event at data cut off were censored on their last tumor assessment

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Reported as:
Median · months
Efficacy of Axitinib in Terms of PFS (Central Blinded Assessment)
monthsAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
Efficacy of Axitinib in Terms of PFS (Central Blinded Assessment)16.6 (13.5 to 24.2)9.9 (8.2 to 13.9)
Statistical analysis
  • Axitinib + Sandostatin LAR vs Placebo + Sandostatin LAR · Regression, Cox · p = 0.017 · Cox proportional hazard: 0.71 · 95% CI 0.54 to 0.94
SecondaryObjective Response Rate (ORR) (Central Blinded Assessment)

Measured changes in the sum of longest diameter of target lesions measured in mm according to RECIST 1.1 criteria. Assessed by central blinded reviewers. Patients are categorized depending on the percentage of tumor redution: Complete response (CR): dissapearance of all lesions Partial response (PR): reduction \> 30% in the sum of longest diameter of target lesions Stable disease (SD): Tumor size betwee 30% reduction and 20% increase in the sum of longest diameter of target lesions Progressive disease (PD): increase \> 20% in the sum of longest diameter of target lesions ORR comprise all patients who achieved at least a CR or PR at any timepoint during follow-up.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 25 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) (Central Blinded Assessment)
ParticipantsAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
Complete response20
Partial response134
Stable disease98109
Progressive disease112
Not evaluable31
Statistical analysis
  • Axitinib + Sandostatin LAR vs Placebo + Sandostatin LAR · Chi-squared, Corrected · p = 0.007 (Threshold of significance pre-established: P-value \< 0.05 will be statistically significant)

Adverse events

Collected over Throughout study period, approximately 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Sandostatin LAR68/125 (54.4%)48/125 (38.4%)121/125 (96.8%)
Placebo + Sandostatin LAR48/130 (36.9%)30/130 (23.1%)124/130 (95.4%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
PyrexiaGeneral disorders0/1254/130
HyperbilirubinaemiaHepatobiliary disorders3/1252/130
DiarrheaGastrointestinal disorders3/1250/130
Intestinal obstructionGastrointestinal disorders3/1253/130
COVID-19Infections and infestations0/1253/130
Angina pectorisCardiac disorders2/1250/130
CholecystitisHepatobiliary disorders2/1250/130
Cholecystitis acuteHepatobiliary disorders2/1250/130
PyrexiaGeneral disorders2/1251/130
Acute coronary syndromeCardiac disorders2/1250/130
Most frequent other events
Showing 10 of 22
Most frequent other events
EventAxitinib + Sandostatin LARPlacebo + Sandostatin LAR
DiarrheaGastrointestinal disorders81/12552/130
HypertensionVascular disorders66/12545/130
AstheniaGeneral disorders66/12545/130
Mucosal inflammationGastrointestinal disorders37/12517/130
Decreased appetiteMetabolism and nutrition disorders33/12516/130
Palmar-plantar erythrodysesthesia syndromeSkin and subcutaneous tissue disorders25/1254/130
AphoniaNervous system disorders19/1251/130
DysphoniaNervous system disorders19/1251/130
NauseaGastrointestinal disorders18/12517/130
HeadacheNervous system disorders18/12515/130

Baseline characteristics

Age, Continuous
Age, Continuous(years)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
Median62 (21 to 85)60 (26 to 83)61 (21 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
Female5563118
Male7167138
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
Count of participants——0
Eastern Cooperative Oncology Group performance status (ECOG-PS)
Eastern Cooperative Oncology Group performance status (ECOG-PS)(Participants)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
Score 07588163
Score 1494190
Score 2101
Unknown112
Tumor grade (WHO)
Tumor grade (WHO)(Participants)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
Grade 1324678
Grade 29483177
Unknown011
Ki-67
Ki-67(Participants)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
ki-67 0-2314374
ki-67 >2-5453984
ki-67 >5 - 10262753
ki-67 >10 - 20231942
Not specified123
Time from initial cancer diagnosis to study entry
Time from initial cancer diagnosis to study entry(Participants)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
≤ 12 months5451105
> 12 months7279151
Primary tumour location
Primary tumour location(Participants)Axitinib + Sandostatin LARPlacebo + Sandostatin LARTotal
Lung383472
Gastric347
Small intestine6067127
Colorectal131124
Unknown primary9716
Other locations3710

8 further baseline measures are reported on the registry.

07

Study locations

26 sites
  • Marburg Universitätsklinikum Giessen und Marburg GmbH
    Marburg, 35043, Germany
  • Azienda Ospedaliera Universitaria di Perugia
    Perugia, 06129, Italy
  • Sapienza, Universitá di Roma, Ospedale sant'Andrea
    Rome, 00189, Italy
  • Institut Català d'Oncologia L'Hospitalet
    L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Malaga 29010, Spain
  • Hospital Alvaro Cunqueiro
    Vigo, Pontevedra 36312, Spain
  • Hospital Central de Asturias
    Oviedo, Principality of Asturias, Spain
  • Complejo Hospitalario Univ A Coruña
    A Coruña, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario de Burgos
    Burgos, Spain
  • Hospital de Donostia
    Donostia / San Sebastian, Spain
  • Hospital Virgen de las Nieves
    Granada, Spain
  • Hospital universitario de Leon
    León, Spain
  • MD Anderson Cancer Center
    Madrid, 28033, Spain
  • Hospital Clara Campal
    Madrid, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital Gregorio Marañón
    Madrid, Spain
  • Hospital Univ La Paz
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
  • Hospital Univ de Salamanca
    Salamanca, Spain
  • Hospital Marqués de Valdecilla
    Santander, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, Spain
  • Clatterbridge Cancer Centre
    Bebington, Wirral CH63 4JY, United Kingdom
08

References and documents

Publications

  • Garcia-Carbonero R, Benavent M, Jimenez-Fonseca P, Alonso-Gordoa T, Teule A, Custodio A, Tafuto S, La Casta A, Spada F, Lopez C, Ibrahim T, Iranzo V, Garcia-Alfonso P, Gonzalez-Flores E, Villanueva Silva MJ, Grande E, Panzuto F, Crespo G, Navarro M, Castellano D, Hernando J, Morales-Herrero R, Iglesias Alvarez G, Soldevilla B, Capdevila J. Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). J Clin Oncol. 2026 Mar 20;44(9):774-786. doi: 10.1200/JCO-25-01808. Epub 2026 Feb 20. PubMed 41719493 ↗
  • Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available. PubMed 33152282 ↗

Study documents

  • Study protocol · Sep 10, 2018
  • Statistical analysis plan · Jan 23, 2020

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT01744249
Lead sponsor
Grupo Espanol de Tumores Neuroendocrinos
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Nov 2011
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Results posted
Apr 28, 2026
Last update
Apr 28, 2026

Study contacts

Rocio Garcia Carbonero, MD
study chair · Hospital 12 de Octubre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion